Clinical Trial Update: Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing donor atorvastatin to prevent severe acute GVHD after nonmyeloablative peripheral blood stem cell transplant in patients with h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Aggressive Adult Non-hodgkin Lymphoma
• Aggressive Non-hodgkin Lymphoma
• Childhood Acute Lymphoblastic Leukemia
• Childhood Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Myelodysplastic Myeloproliferative Neoplasm
• Myelogenous Leukemia Bcr-abl1 Positive
• Non-hodgkin Lymphoma
• Plasma Cell Myeloma
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma
• Waldenstrom Macroglobulinemia

Drugs mentioned

• atorvastatin (atorvastatin)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Phase 2 | Status: COMPLETED | Results posted: 2019-11-22